Malaria vaccine - Aventis Pasteur/WRAIR

Drug Profile

Malaria vaccine - Aventis Pasteur/WRAIR

Alternative Names: NYVAC-Pf7A

Latest Information Update: 31 Oct 2008

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Nonindustrial source; sanofi pasteur
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Falciparum malaria

Most Recent Events

  • 24 Dec 1999 Pasteur Mérieux Connaught is now a subsidiary of Aventis and its new name is Aventis Pasteur
  • 12 Mar 1999 New profile, split from generic Malaria vaccine profile
  • 12 Mar 1999 Phase-II clinical trials for Falciparum malaria in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top